TD-1058 / Theravance Biopharma - LARVOL DELTA

TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P1 | N=72 | Terminated | Sponsor: Theravance Biopharma | Recruiting ➔ Terminated | Trial primary completion date: Dec 2021 ➔ May 2021; The Sponsor has decided to stop the study due to business reasons. Study was terminated before initiation of part C and D (Decision to not proceed with Parts C and D was not for safety reasons and do not impact the overall risk benefit of the IMP.)

Trial primary completion date • Trial termination • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P1; N=96; Recruiting; Sponsor: Theravance Biopharma; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Respiratory Diseases

TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P1; N=96; Not yet recruiting; Sponsor: Theravance Biopharma

Clinical • New P1 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Respiratory Diseases

Edited Transcript of TBPH.OQ earnings conference call or presentation 6-Aug-20 9:00pm GMT (Yahoo Finance) - "And the next program up, likely to go into Phase I is our nebulized ALK5 inhibitor, targeted at idiopathic pulmonary fibrosis and perhaps other conditions in the lung....I think it's likely that we get into the clinic this year with the inhaled ALK5 inhibitor, and we'll be progressing from there."

Clinical • Idiopathic Pulmonary Fibrosis